ArticlePLoS neglected tropical diseases2026
Chikungunya virus in dengue-suspected patients: Molecular evidence from the 2019 outbreak in Yangon, Myanmar.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChikungunya virus (CHIKV) and dengue virus (DENV) frequently co-occur in Myanmar and present with overlapping symptoms, complicating diagnosis. During the 2019 dengue outbreak in Yangon, Myanmar, molecular data on CHIKV were limited among dengue-suspected patients and there were no publicly available CHIKV genome sequences from Yangon in international databases. To address this gap and potential diagnostic overlap, we investigated the prevalence of CHIKV infection and described the genomic characteristics of detected strains.
methodsSerum samples from 267 dengue-suspected patients collected in 2019 were screened for anti-CHIKV IgM and IgG by in-house ELISA and 211 samples with sufficient remaining volume were further analyzed by RT-qPCR, isolation of the virus, and whole-genome sequencing for mutation analysis.
resultsCHIKV antibodies were found in 24.7% (66/267) of samples (IgM 3.4%, IgG 21.3%), and viral RNA was detected in 10.9% (23/211) of samples. Fifteen viral isolates were successfully obtained (7.1% of those tested), including two co-detections with DENV-2 by RT-PCR. All isolates belonged to the East/Central/South African genotype, Indian Ocean Lineage (ECSA-IOL), and clustered with strains from Thailand, China, and Mandalay, Myanmar. Whole-genome analysis identified 33 non-synonymous mutations across nonstructural and structural proteins, including mutations previously reported in regional ECSA-IOL strains such as E1:K211E and E2:V264A, with 11 amino acid changes not previously reported in available Myanmar reference sequences. DISCUSSION: Serological and molecular findings indicate CHIKV circulation during the 2019 dengue outbreak in Yangon and highlight the limitations of single-target testing. Serological evidence indicate the presence of anti-CHIKV IgM and IgG antibodies, reflecting CHIKV exposure within the study population. Notably, all RNA-positive cases were seronegative for both IgM and IgG, a pattern consistent with the temporal dynamics of infection and the inherent constraints of serological detection in co-endemic settings. Molecular co-detection with DENV-2 and genomic findings highlight the potential value of multiplex diagnostic approaches in co-endemic settings.
conclusionThis study documents CHIKV detection and genomic characterization in dengue-suspected patients in Yangon and highlights the potential value of multiplex diagnostic approaches and continued genomic surveillance as broader public health considerations for arboviral detection in Myanmar.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.